MIRIAD IBD Biobank & Database

The Material and Information Resources for Inflammatory and Digestive Diseases (MIRIAD) Biobank is the central hub of a full-circle approach to the study of inflammatory bowel disease (IBD). MIRIAD acquires, processes, stores, evaluates and distributes human specimens, which are maintained in association with the triad of accurate longitudinal clinical metadata, comprehensive genotype information and serotypes. These resources are made available to research partners within IBIRI and Cedars-Sinai, and with collaborators around the world.

Specimens have been collected from thousands of subjects over 3 decades. Clinical and research data are stored in an extensive database/LIMS system customized specifically for this purpose. The database is also used to monitor subject participation, assure regulatory compliance and to manage inventory. Collectively, MIRIAD's capabilities permit the rapid assembly and dispersal of homogenous cohorts for investigation.

MIRIAD provides both "fresh" specimens for immediate use, as well as archived specimens. Specimen types include:

  • Blood-derived resources (whole blood, isolated cell populations, serum/plasma, EBV transformed lymphoblastoid cell lines) 
  • Surgically or endoscopically obtained resources (isolated cells from resected or biopsied tissue, slides from formalin-fixed paraffin embedded blocks (FFPE), lymph nodes, subcutaneous and mesenteric fat, endoscopic biopsy tissue samples, colonic lavage fluid) 
  • Other materials (stool, saliva, urine)

MIRIAD also provides serotyping, genotyping and metabotyping services. These data are summarized and entered into the database, allowing for identification and stratification of subjects based on: clinical parameters, the principal IBD-related autoantibodies (ANCA, ASCA, OmpC, I2, and CBir1); and genetic parameters including IBD-susceptibility variants (>200). The raw genotype data generated by all platforms can easily be interrogated for researchers and added to the database as interest in additional genes evolves. Genotype data has been generated by genome-wide platforms, as well as by more targeted platforms including Immunochip, exome chip and Metabochip.


Clinical data, disease history, demographic and health status information obtained as part of regular medical care or, as approved, for research purposes only are collected from consenting subjects and maintained in our database. Genotype data for all established IBD loci (> 200), as well as genetic information for loci and SNPs of specific interest to investigators are summarized for each subject in the database, allowing for convenient genotype-based searches and facilitating gene-specific sampling and recruitment. This list of additional genetic variants is easily adjusted as researchers' interests evolve.

Cedars-Sinai has financial interests in Prometheus Biosciences, Inc., a company which has access to the data and specimens in Cedars-Sinai’s MIRIAD Biobank and seeks to develop commercial products.

Have Questions or Need Help?

Contact us if you have questions, or wish to learn more about the IBIRI.

Inflammatory Bowel & Immunobiology Research Institute
8700 Beverly Blvd.
Davis Building, Suite D4063
Los Angeles CA 90048